Strain Name:

B6.129S2-Serpine1tm1Mlg/J

Stock Number:

002507

Availability:

Repository- Live

Description

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating SystemHomozygote x Homozygote         (Female x Male)
Specieslaboratory mouse
Background Strain C57BL/6J
Donor Strain 129S2 via D3 ES cell line
GenerationN8F15N1F4 (30-DEC-08)
 
Donating Investigator Peter Carmeliet,   University of Leuven

Appearance
black
Related Genotype: a/a

Description
Mice homozygous for this mutation develop normally and are viable and fertile. Compared to wild type mice, pulmonary clot lysis is increased in the heterozygote and further increased in the homozygote. Endotoxin induced venous thrombosis is decreased compared to wild type mice. Thus, disruption of the Serpine1 gene induces a mild hyperfibrinolytic state. Hemostasis is normal in homozygous mutants.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Serpine1tm1Mlg allele
002324   FVB.129S2-Serpine1tm1Mlg/J
View Strains carrying   Serpine1tm1Mlg     (1 strain)

Strains carrying other alleles of Serpine1
007237   B6.Cg-Tg(CMV-Serpine1)1Dgi/J
View Strains carrying other alleles of Serpine1     (1 strain)

Additional Web Information

Congenic Nomenclature

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms
      assigned by genotype

Serpine1tm1Mlg/Serpine1tm1Mlg

        B6.129S2-Serpine1tm1Mlg/J
  • cardiovascular system phenotype
  • cardiac fibrosis (MGI Ref ID J:101486)
    • older mutants develop cardiac fibrosis, however fibrosis is not seen in the liver, spleen, lungs or kidneys and do not develop small vessel disease
  • heart inflammation (MGI Ref ID J:101486)
    • older mutants exhibit significantly more macrophages in the heart
  • increased angiogenesis (MGI Ref ID J:108675)
    • aortic vessel explants show increased capillary sprouting in both collagen lattices and Matrigel
  • immune system phenotype
  • heart inflammation (MGI Ref ID J:101486)
    • older mutants exhibit significantly more macrophages in the heart

Serpine1tm1Mlg/Serpine1tm1Mlg

        B6.129S2-Serpine1tm1Mlg
  • life span-post-weaning/aging
  • abnormal induced morbidity/mortality (MGI Ref ID J:124327)
    • following infection with live Streptococcus pneumoniae, S. pneumoniae wild-type lysate, and S. pneumoniae pneumolysin (PLY), mice begin to die earlier and are all dead by 5 days post-infection
    • following infection with S. pneumoniae strain ATCC 6303 (a more virulent strain), mortality is increased (10% survival compared to 45% in wild-type mice)
  • immune system phenotype
  • increased susceptibility to bacterial infection (MGI Ref ID J:124327)
    • following infection with live Streptococcus pneumoniae, S. pneumoniae wild-type lysate, and S. pneumoniae pneumolysin (PLY), mice begin to die earlier and are all dead by 5 days post-infection
    • following infection with S. pneumoniae, acute lung injury and alveolar hemorrhage is enhanced
    • following infection with S. pneumoniae strain ATCC 6303 (a more virulent strain), mortality is increased (10% survival compared to 45% in wild-type mice)
  • liver/biliary system phenotype
  • *normal* liver/biliary system phenotype (MGI Ref ID J:123733)
    • stellate cell activation, TGFbeta-1 and collagen synthesis are similar in mutants and controls before and after bile duct ligation
    • liver fibrosis (MGI Ref ID J:123733)
      • 3 weeks after bile duct ligation (BDL), hepatic fibrosis is reduced 18-26% compared to wild-type; hepatic collagen content is similar to sham-operated wild-type
  • homeostasis/metabolism phenotype
  • abnormal enzyme/coenzyme activity (MGI Ref ID J:123733)
    • 3 weeks after BDL, urokinase plasminogen activator (uPA) and plasmin activity are not increased in mutants but tissue-type plasminogen activator (tPA) activity is significantly increased relative to wild-type
    • 3 weeks after BDL, pro-MMP-9 and MMP-9 activities in liver homogenates from mutants are increased significantly compared to wild-type controls

The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.

Serpine1tm1Mlg/Serpine1tm1Mlg

        involves: 129S2/SvPas * C57BL/6
  • growth/size phenotype
  • abnormal body weight (MGI Ref ID J:87982)
    • less weight gain on a high fat diet than normal
    • decreased body weight (MGI Ref ID J:133227)
      • at 2 weeks, mutants remain below initial body weight after turpentine injection-induced weight loss but wild-type mice recover and begin to gain weight around 6-7 days after injection
      • weight loss (MGI Ref ID J:133227)
        • turpentine injection induces significant weight loss in mutants and wild-type mice in initial 2 days; however, after 2 days, wild-type animals start to recover body weight whereas mutants do not
  • immune system phenotype
  • *normal* immune system phenotype (MGI Ref ID J:133227)
    • chemokine levels in injured tissue are similar between mutants and controls, peaking at 1-3 days
    • abnormal acute inflammation (MGI Ref ID J:133227)
      • in mutants after turpentine injection, serum amyloid P and C3 are significantly lower at 24 hours compared to wild-type and display a delayed peak at 3 days after injection
      • C3 peak levels at day 3 are higher than in wild-type
      • haptoglobin levels do not differ from wild-type at any time after turpentine injection
      • increased acute inflammation (MGI Ref ID J:133227)
        • after turpentine injection to hind limb to induce tissue injury, 8 week-old mutants show significantly more local tissue injury compared to controls
        • treatment resulted in local abscess formation and neutrophilic granulocyte infiltration encapsulated by macrophages and fibroblasts
    • abnormal interleukin level (MGI Ref ID J:133227)
      • local Il6 levels in injured tissue at 8 hours post-injection are lower than in controls
      • decreased circulating interleukin-6 level (MGI Ref ID J:133227)
        • plasma levels are markedly reduced at 8 hours after turpentine injection
    • glomerulonephritis (MGI Ref ID J:85989)
      • higher incidence of fibrin positive crescents
      • increased infiltration of injury with CD4+ T cells
      • increased mortality
      • increased thrombin production
    • increased granulocyte number (MGI Ref ID J:133227)
      • relative to controls following turpentine injection
    • respiratory system inflammation (MGI Ref ID J:66093)
      • inflammation induced fibrosis in the lung occurs at a much slower rate
      • survival is better
      • fibrin content of lungs reduced generally
  • renal/urinary system phenotype
  • glomerulonephritis (MGI Ref ID J:85989)
    • higher incidence of fibrin positive crescents
    • increased infiltration of injury with CD4+ T cells
    • increased mortality
    • increased thrombin production
  • proteinuria (MGI Ref ID J:85989)
    • an earlier enhancement of protein urea
  • cardiovascular system phenotype
  • abnormal blood circulation (MGI Ref ID J:67531)
    • injury response in carotid arteries is reduced although cell proliferation in the adventitia is increased
    • no fibrin present in the injured vessel walls
  • decreased angiogenesis (MGI Ref ID J:65383)
    • neovascularization in general is reduced
  • hematopoietic system phenotype
  • *normal* hematopoietic system phenotype (MGI Ref ID J:39819)
    • bleeding time was normal
    • increased granulocyte number (MGI Ref ID J:133227)
      • relative to controls following turpentine injection
  • respiratory system phenotype
  • abnormal lung morphology (MGI Ref ID J:31542)
    • no significant bleomycin-induced increase in lung collagen content is detected at 3 weeks posttreatment whereas treated wild-type mice show a significant increase in lung collagen; heterozygous mice are intermediate between null and wild-type in terms of collagen content
    • lung fibrin deposition following bleomycin treatment is almost undetectable compared to treated wild-type mice
  • respiratory system inflammation (MGI Ref ID J:66093)
    • inflammation induced fibrosis in the lung occurs at a much slower rate
    • survival is better
    • fibrin content of lungs reduced generally
  • adipose tissue phenotype
  • abnormal epididymal fat pad morphology (MGI Ref ID J:87982)
    • after 12 weeks on a high fat diet, epididymal fat pad was only 25% of wild-type
  • decreased subcutaneous adipose tissue amount (MGI Ref ID J:87982)
    • subcutaneous white fat pad mass was also reduced
  • tumorigenesis
  • *normal* tumorigenesis (MGI Ref ID J:33232)
    • no significant differences are observed compared to controls in terms of primary tumor size of footpad tumors induced by foot pad injection with tumor cells at 10, 17, or 21 days post-injection
    • after injection of melanoma cells, number of primary pulmonary metastases post-injection, or tumor burdens initiated by injections of increasing doses of cells do not significantly differ from wild-type controls
    • survival times after foot pad tumor removal are not significantly different among Serpine1-deficient, Serpine1-overexpressing transgenic, or wild-type mice
    • altered tumor susceptibility (MGI Ref ID J:65383)
      • very little metastasis
      • more apoptosis seen
      • vascular density in tumors reduced and lumens of vessels are small
  • homeostasis/metabolism phenotype
  • abnormal energy expenditure (MGI Ref ID J:87982)
    • increased after 12 weeks on a high fat diet
  • abnormal enzyme/coenzyme activity (MGI Ref ID J:133227)
    • after 8 hours, myeloperoxidase (MPO) activity is higher in mutants in hind limb homogenates than in wild-type
  • abnormal interleukin level (MGI Ref ID J:133227)
    • local Il6 levels in injured tissue at 8 hours post-injection are lower than in controls
    • decreased circulating interleukin-6 level (MGI Ref ID J:133227)
      • plasma levels are markedly reduced at 8 hours after turpentine injection
  • decreased triglyceride level (MGI Ref ID J:87982)
    • lower levels in both skeletal muscle and liver after 12 weeks on a high fat diet
  • enhanced wound healing (MGI Ref ID J:72394)
    • dermal incisions healed more rapidly than normal
    • thickened epidermal layer found within newly healed wounds
  • increased body temperature (MGI Ref ID J:87982)
    • increased on a high fat diet
  • increased oxygen consumption (MGI Ref ID J:87982)
    • after 12 weeks on a high fat diet, oxygen consumption is increased
  • proteinuria (MGI Ref ID J:85989)
    • an earlier enhancement of protein urea

Serpine1tm1Mlg/Serpine1tm1Mlg

        involves: 129S2/SvPas * C57BL/6 * C57BLKS/J
  • homeostasis/metabolism phenotype
  • *normal* homeostasis/metabolism phenotype (MGI Ref ID J:127478)
    • mice do not develop significant albuminuria after 6 months of streptozotocin (STZ) -induced diabetes
    • decreased circulating cholesterol level (MGI Ref ID J:127478)
      • mean levels are significantly lower than in wild-type controls and STZ-treated mutants
    • hyperglycemia (MGI Ref ID J:127478)
      • in streptozotocin-treated (STZ) mice (to induce diabetes), serum glucose is significantly increased compared to untreated mutant or wild-type controls
    • increased blood urea nitrogen level (MGI Ref ID J:127478)
      • STZ-treated mutants show elevated BUN levels compared to untreated mice, but levels are comparable to STZ-treated wild-type
  • renal/urinary system phenotype
  • abnormal kidney morphology (MGI Ref ID J:127478)
    • total kidney collagen in STZ-treated mice increases only 8% compared to 40% in treated wild-type
    • abnormal renal glomerulus morphology (MGI Ref ID J:127478)
      • glomerular extracellular matrix (ECM) area is greater than in wild-type controls; however, when expressed as fractional glomerular ECM area, little difference is observed between any genotype
      • glomerular extracellular matrix (ECM) area is significantly higher compared to controls; after 6 months of STZ-induced diabetes, ECM area is decreased 15% compared to Serpine1 single deficient mice while in STZ-treated wild-type mice, ECM area is increased 64% relative to untreated wild-type mice
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Serpine1tm1Mlg related

Cancer Research
Defects in Cell Adhesion Molecules

Internal/Organ Research
Wound Healing (enhanced)

Genes & Alleles

Gene & Allele Information

 
Allele Symbol Serpine1tm1Mlg
Allele Name targeted mutation 1, Richard C Mulligan
Allele Type Targeted (knock-out)
Common Name(s) PAI-1-; Planh1tm1;
Mutation Made By Peter Carmeliet,   University of Leuven
Strain of Origin129S2/SvPas
ES Cell Line NameD3
ES Cell Line Strain129S2/SvPas
Gene Symbol and Name Serpine1, serine (or cysteine) peptidase inhibitor, clade E, member 1
Chromosome 5
Gene Common Name(s) PAI; PAI-1; PAI1; PLANH1; Planh1; plasminogen activator inhibitor, type I;
Molecular Note A PGK-neomycin resistance cassette replaced all of the Serpine1 coding sequence and part of the promoter region including the transcription initiation site. Northern blot analysis did not detect Serpine1 mRNA in endotoxin-treated homozygous mutant liver. Neither untreated nor endotoxin-treated homozygous mutant kidney produced detectable SERPINE1 immunoreactivity. A monoclonal antibody based immunofunctional assay did not detect protein levels in plasma of endotoxin-treated homozygous mutant mice. [MGI Ref ID J:39819]

Genotyping

Genotyping Information

Genotyping Protocols

Serpine1tm1Mlg, STD PCR, vers. 1

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Carmeliet P; Kieckens L; Schoonjans L; Ream B; van Nuffelen A; Prendergast G; Cole M; Bronson R; Collen D; Mulligan RC. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92(6):2746-55. [PubMed: 8254028]  [MGI Ref ID J:39819]

Additional References

Carmeliet P; Stassen JM; Schoonjans L; Ream B; van den Oord JJ; De Mol M; Mulligan RC; Collen D. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92(6):2756-60. [PubMed: 8254029]  [MGI Ref ID J:67715]

Chan JC; Duszczyszyn DA; Castellino FJ; Ploplis VA. 2001. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159(5):1681-8. [PubMed: 11696429]  [MGI Ref ID J:72394]

Hattori N; Mizuno S; Yoshida Y; Chin K; Mishima M; Sisson TH; Simon RH; Nakamura T; Miyake M. 2004. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 164(3):1091-8. [PubMed: 14982862]  [MGI Ref ID J:88462]

Ma LJ; Mao SL; Taylor KL; Kanjanabuch T; Guan Y; Zhang Y; Brown NJ; Swift LL; McGuinness OP; Wasserman DH; Vaughan DE; Fogo AB. 2004. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53(2):336-46. [PubMed: 14747283]  [MGI Ref ID J:87982]

Serpine1tm1Mlg related

Almholt K; Nielsen BS; Frandsen TL; Brunner N; Dano K; Johnsen M. 2003. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 22(28):4389-97. [PubMed: 12853975]  [MGI Ref ID J:84633]

Arndt PG; Young SK; Worthen GS. 2005. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway. J Immunol 175(6):4049-59. [PubMed: 16148154]  [MGI Ref ID J:116702]

Bajou K; Maillard C; Jost M; Lijnen RH; Gils A; Declerck P; Carmeliet P; Foidart JM; Noel A. 2004. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23(41):6986-90. [PubMed: 15286708]  [MGI Ref ID J:93782]

Bajou K; Noel A; Gerard RD; Masson V; Brunner N; Holst-Hansen C; Skobe M; Fusenig NE; Carmeliet P; Collen D; Foidart JM. 1998. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4(8):923-8. [PubMed: 9701244]  [MGI Ref ID J:49535]

Bajou K; Peng H; Laug WE; Maillard C; Noel A; Foidart JM; Martial JA; DeClerck YA. 2008. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 14(4):324-34. [PubMed: 18835034]  [MGI Ref ID J:140088]

Bajt ML; Yan HM; Farhood A; Jaeschke H. 2008. Plasminogen activator inhibitor-1 limits liver injury and facilitates regeneration after acetaminophen overdose. Toxicol Sci 104(2):419-27. [PubMed: 18469330]  [MGI Ref ID J:139782]

Balsara RD; Castellino FJ; Ploplis VA. 2006. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 281(32):22527-36. [PubMed: 16785241]  [MGI Ref ID J:116488]

Bergheim I; Guo L; Davis MA; Duveau I; Arteel GE. 2006. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 316(2):592-600. [PubMed: 16221737]  [MGI Ref ID J:136744]

Brodsky S; Chen J; Lee A; Akassoglou K; Norman J; Goligorsky MS. 2001. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am J Physiol Heart Circ Physiol 281(4):H1784-92. [PubMed: 11557572]  [MGI Ref ID J:108675]

Carmeliet P; Stassen JM; Schoonjans L; Ream B; van den Oord JJ; De Mol M; Mulligan RC; Collen D. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92(6):2756-60. [PubMed: 8254029]  [MGI Ref ID J:67715]

Chan JC; Duszczyszyn DA; Castellino FJ; Ploplis VA. 2001. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159(5):1681-8. [PubMed: 11696429]  [MGI Ref ID J:72394]

Chuang-Tsai S; Sisson TH; Hattori N; Tsai CG; Subbotina NM; Hanson KE; Simon RH. 2003. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 163(2):445-52. [PubMed: 12875966]  [MGI Ref ID J:109418]

Collins SJ; Alexander SL; Lopez-Guisa JM; Cai X; Maruvada R; Chua SC; Zhang G; Okamura DM; Matsuo S; Eddy AA. 2006. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol 104(1):e23-34. [PubMed: 16735799]  [MGI Ref ID J:127478]

De Taeye BM; Novitskaya T; Gleaves L; Covington JW; Vaughan DE. 2006. Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem 281(43):32796-805. [PubMed: 16931518]  [MGI Ref ID J:117279]

Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg. 1996. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87(11):4718-22. [PubMed: 8639841]  [MGI Ref ID J:33232]

Eitzman DT; McCoy RD; Zheng X; Fay WP; Shen T; Ginsburg D; Simon RH. 1996. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97(1):232-7. [PubMed: 8550840]  [MGI Ref ID J:31542]

Eitzman DT; Westrick RJ; Nabel EG; Ginsburg D. 2000. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 95(2):577-80. [PubMed: 10627465]  [MGI Ref ID J:110259]

Eitzman DT; Westrick RJ; Xu Z; Tyson J; Ginsburg D. 2000. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96(13):4212-5. [PubMed: 11110693]  [MGI Ref ID J:106740]

Fen Li C; Kandel C; Baliko F; Nadesan P; Brunner N; Alman BA. 2005. Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor). Oncogene 24(9):1615-24. [PubMed: 15674349]  [MGI Ref ID J:96994]

Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ. 2000. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1 Cancer Res 60(20):5839-47. [PubMed: 11059781]  [MGI Ref ID J:65383]

Hattori N; Degen JL; Sisson TH; Liu H; Moore BB; Pandrangi RG; Simon RH; Drew AF. 2000. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice J Clin Invest 106(11):1341-50. [PubMed: 11104787]  [MGI Ref ID J:66093]

Hattori N; Mizuno S; Yoshida Y; Chin K; Mishima M; Sisson TH; Simon RH; Nakamura T; Miyake M. 2004. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 164(3):1091-8. [PubMed: 14982862]  [MGI Ref ID J:88462]

Hertig A; Berrou J; Allory Y; Breton L; Commo F; Costa De Beauregard MA; Carmeliet P; Rondeau E. 2003. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J 17(13):1904-6. [PubMed: 12897066]  [MGI Ref ID J:85989]

Jost M; Maillard C; Lecomte J; Lambert V; Tjwa M; Blaise P; Alvarez Gonzalez ML; Bajou K; Blacher S; Motte P; Humblet C; Defresne MP; Thiry M; Frankenne F; Gothot A; Carmeliet P; Rakic JM; Foidart JM; Noel A. 2007. Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I. Am J Pathol 171(4):1369-80. [PubMed: 17717143]  [MGI Ref ID J:125522]

Kawasaki T; Dewerchin M; Lijnen HR; Vermylen J; Hoylaerts MF. 2000. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 96(1):153-60. [PubMed: 10891445]  [MGI Ref ID J:63087]

Kawasaki T; Dewerchin M; Lijnen HR; Vreys I; Vermylen J; Hoylaerts MF. 2001. Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development. Circ Res 88(2):159-66. [PubMed: 11157667]  [MGI Ref ID J:115383]

Keller TT; van der Sluijs KF; de Kruif MD; Gerdes VE; Meijers JC; Florquin S; van der Poll T; van Gorp EC; Brandjes DP; Buller HR; Levi M. 2006. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 99(11):1261-9. [PubMed: 17068293]  [MGI Ref ID J:129084]

Koh TJ; Bryer SC; Pucci AM; Sisson TH. 2005. Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. Am J Physiol Cell Physiol 289(1):C217-23. [PubMed: 15716324]  [MGI Ref ID J:104684]

Koschnick S; Konstantinides S; Schafer K; Crain K; Loskutoff DJ. 2005. Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. J Thromb Haemost 3(10):2290-5. [PubMed: 16194205]  [MGI Ref ID J:114352]

Krag S; Danielsen CC; Carmeliet P; Nyengaard J; Wogensen L. 2005. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int 68(6):2651-66. [PubMed: 16316341]  [MGI Ref ID J:116902]

Lambert V; Munaut C; Noel A; Frankenne F; Bajou K; Gerard R; Carmeliet P; Defresne MP; Foidart JM; Rakic JM. 2001. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 15(6):1021-7. [PubMed: 11292663]  [MGI Ref ID J:120446]

Lazar MH; Christensen PJ; Du M; Yu B; Subbotina NM; Hanson KE; Hansen JM; White ES; Simon RH; Sisson TH. 2004. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol 31(6):672-8. [PubMed: 15308506]  [MGI Ref ID J:104660]

Leonardsson G; Peng XR; Liu K; Nordstrom L; Carmeliet P; Mulligan R; Collen D; Ny T. 1995. Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Natl Acad Sci U S A 92(26):12446-50. [PubMed: 8618918]  [MGI Ref ID J:31086]

Liang X; Kanjanabuch T; Mao SL; Hao CM; Tang YW; Declerck PJ; Hasty AH; Wasserman DH; Fogo AB; Ma LJ. 2006. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 290(1):E103-E113. [PubMed: 16144810]  [MGI Ref ID J:115737]

Lim JH; Stirling B; Derry J; Koga T; Jono H; Woo CH; Xu H; Bourne P; Ha UH; Ishinaga H; Xu H; Andalibi A; Feng XH; Zhu H; Huang Y; Zhang W; Weng X; Yan C; Yin Z; Briles DE; Davis RJ; Flavell RA; Li JD. 2007. Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections. Immunity 27(2):349-60. [PubMed: 17723219]  [MGI Ref ID J:124327]

Luttun A; Lupu F; Storkebaum E; Hoylaerts MF; Moons L; Crawley J; Bono F; Poole AR; Tipping P; Herbert JM; Collen D; Carmeliet P. 2002. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 22(3):499-505. [PubMed: 11884297]  [MGI Ref ID J:102938]

Ma J; Weisberg A; Griffin JP; Vaughan DE; Fogo AB; Brown NJ. 2006. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69(6):1064-72. [PubMed: 16528256]  [MGI Ref ID J:136504]

Ma LJ; Mao SL; Taylor KL; Kanjanabuch T; Guan Y; Zhang Y; Brown NJ; Swift LL; McGuinness OP; Wasserman DH; Vaughan DE; Fogo AB. 2004. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53(2):336-46. [PubMed: 14747283]  [MGI Ref ID J:87982]

Matsushita M; Yamamoto T; Nishioka K. 2005. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol 139(3):429-38. [PubMed: 15730388]  [MGI Ref ID J:96321]

McMahon GA; Petitclerc E; Stefansson S; Smith E; Wong MK; Westrick RJ; Ginsburg D; Brooks PC; Lawrence DA. 2001. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276(36):33964-8. [PubMed: 11441025]  [MGI Ref ID J:120509]

Milliat F; Sabourin JC; Tarlet G; Holler V; Deutsch E; Buard V; Tamarat R; Atfi A; Benderitter M; Francois A. 2008. Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy. Am J Pathol 172(3):691-701. [PubMed: 18276785]  [MGI Ref ID J:132273]

Moriwaki H; Stempien-Otero A; Kremen M; Cozen AE; Dichek DA. 2004. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95(6):637-44. [PubMed: 15297377]  [MGI Ref ID J:101486]

Nagai N; De Mol M; Lijnen HR; Carmeliet P; Collen D. 1999. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 99(18):2440-4. [PubMed: 10318667]  [MGI Ref ID J:55243]

Nicholas SB; Aguiniga E; Ren Y; Kim J; Wong J; Govindarajan N; Noda M; Wang W; Kawano Y; Collins A; Hsueh WA. 2005. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67(4):1297-307. [PubMed: 15780082]  [MGI Ref ID J:110122]

Nishiuma T; Sisson TH; Subbotina N; Simon RH. 2004. Localization of plasminogen activator activity within normal and injured lungs by in situ zymography. Am J Respir Cell Mol Biol 31(5):552-8. [PubMed: 15284078]  [MGI Ref ID J:103595]

Oda T; Jung YO; Kim HS; Cai X; Lopez-Guisa JM; Ikeda Y; Eddy AA. 2001. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60(2):587-96. [PubMed: 11473641]  [MGI Ref ID J:103959]

Oh CK; Ariue B; Alban RF; Shaw B; Cho SH. 2002. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 294(5):1155-60. [PubMed: 12074598]  [MGI Ref ID J:113534]

Otsuka G; Agah R; Frutkin AD; Wight TN; Dichek DA. 2006. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 26(4):737-43. [PubMed: 16373605]  [MGI Ref ID J:127967]

Otsuka G; Stempien-Otero A; Frutkin AD; Dichek DA. 2007. Mechanisms of TGF-beta1-induced intimal growth: plasminogen-independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. Circ Res 100(9):1300-7. [PubMed: 17431190]  [MGI Ref ID J:137777]

Pinsky DJ; Liao H; Lawson CA; Yan SF; Chen J; Carmeliet P; Loskutoff DJ; Stern DM. 1998. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 102(5):919-28. [PubMed: 9727060]  [MGI Ref ID J:112025]

Ploplis VA; Cornelissen I; Sandoval-Cooper MJ; Weeks L; Noria FA; Castellino FJ. 2001. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol 158(1):107-17. [PubMed: 11141484]  [MGI Ref ID J:67531]

Renckens R; Pater JM; van der Poll T. 2006. Plasminogen activator inhibitor type-1-deficient mice have an enhanced IFN-gamma response to lipopolysaccharide and staphylococcal enterotoxin B. J Immunol 177(11):8171-6. [PubMed: 17114493]  [MGI Ref ID J:140679]

Renckens R; Roelofs JJ; de Waard V; Florquin S; Lijnen HR; Carmeliet P; van der Poll T. 2005. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 3(5):1018-25. [PubMed: 15869599]  [MGI Ref ID J:133227]

Rijneveld AW; Florquin S; Bresser P; Levi M; De Waard V; Lijnen R; Van Der Zee JS; Speelman P; Carmeliet P; Van Der Poll T. 2003. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 102(3):934-9. [PubMed: 12702502]  [MGI Ref ID J:115706]

Rossignol P; Luttun A; Martin-Ventura JL; Lupu F; Carmeliet P; Collen D; Angles-Cano E; Lijnen HR. 2006. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost 4(3):664-70. [PubMed: 16460449]  [MGI Ref ID J:135792]

Savov JD; Brass DM; Berman KG; McElvania E; Schwartz DA. 2003. Fibrinolysis in LPS-induced chronic airway disease. Am J Physiol Lung Cell Mol Physiol 285(4):L940-8. [PubMed: 12818888]  [MGI Ref ID J:108631]

Schaefer U; Machida T; Vorlova S; Strickland S; Levi R. 2006. The plasminogen activator system modulates sympathetic nerve function. J Exp Med 203(9):2191-200. [PubMed: 16940168]  [MGI Ref ID J:124557]

Schafer K; Fujisawa K; Konstantinides S; Loskutoff DJ. 2001. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 15(10):1840-2. [PubMed: 11481248]  [MGI Ref ID J:70695]

Scroyen I; Christiaens V; Lijnen HR. 2007. No functional role of plasminogen activator inhibitor-1 in murine adipogenesis or adipocyte differentiation. J Thromb Haemost 5(1):139-45. [PubMed: 17067365]  [MGI Ref ID J:135923]

Sejima T; Madoiwa S; Mimuro J; Sugo T; Okada K; Ueshima S; Matsuo O; Ishida T; Ichimura K; Sakata Y. 2005. Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol 174(12):8135-43. [PubMed: 15944322]  [MGI Ref ID J:100893]

Shah C; Yang G; Lee I; Bielawski J; Hannun YA; Samad F. 2008. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 283(20):13538-48. [PubMed: 18359942]  [MGI Ref ID J:137080]

Sjoland H; Eitzman DT; Gordon D; Westrick R; Nabel EG; Ginsburg D. 2000. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 20(3):846-52. [PubMed: 10712412]  [MGI Ref ID J:61287]

Smith LH; Dixon JD; Stringham JR; Eren M; Elokdah H; Crandall DL; Washington K; Vaughan DE. 2006. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 107(1):132-4. [PubMed: 16160004]  [MGI Ref ID J:126198]

Thomsen M; Woldbye DP; Wortwein G; Fink-Jensen A; Wess J; Caine SB. 2005. Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. J Neurosci 25(36):8141-9. [PubMed: 16148222]  [MGI Ref ID J:100892]

Wang H; Zhang Y; Heuckeroth RO. 2007. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 581(16):3098-104. [PubMed: 17561000]  [MGI Ref ID J:123733]

Yamamoto K; Takeshita K; Shimokawa T; Yi H; Isobe K; Loskutoff DJ; Saito H. 2002. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A 99(2):890-5. [PubMed: 11792849]  [MGI Ref ID J:73984]

Yepes M; Sandkvist M; Coleman TA; Moore E; Wu JY; Mitola D; Bugge TH; Lawrence DA. 2002. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 109(12):1571-8. [PubMed: 12070304]  [MGI Ref ID J:120679]

Zhu Y; Carmeliet P; Fay WP. 1999. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 99(23):3050-5. [PubMed: 10368124]  [MGI Ref ID J:103348]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX12

Colony Maintenance

Mating SystemHomozygote x Homozygote         (Female x Male)
Diet Information LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Pricing for USA, Canada and Mexico shipping destinations View International pricing
Weeks of AgePrice (US dollars $)GenderGenotypes Provided
Individual Mouse Price $83.30Female or MaleHomozygous for Serpine1tm1Mlg
Pairs /Price (US dollars $)Pair Genotype
$166.60Homozygous for Serpine1tm1Mlg x Homozygous for Serpine1tm1Mlg

Additional Supply Details

Pricing for International shipping destinations View USA Canada and Mexico pricing
Weeks of AgePrice (US dollars $)GenderGenotypes Provided
Individual Mouse Price $108.30Female or MaleHomozygous for Serpine1tm1Mlg
Pairs /Price (US dollars $)Pair Genotype
$216.60Homozygous for Serpine1tm1Mlg x Homozygous for Serpine1tm1Mlg

Additional Supply Details

Supply Details

Standard SupplyRepository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement.
Supply Notes

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
  International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions


See Terms of Use


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering and Purchasing Information

      Purchasing Information
      JAX® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries

Contracts Administration

phone:207-288-6470
fax:207-288-6655

JAX® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.


(3.4)